Business Context and Reporting Period
Company: Nephros, Inc.
Filing Type: Form 8-K (Current Report)
Date of Report: May 9, 2024
Reporting Period: First Quarter 2024
This filing serves as a notification that the Company issued a press release on May 9, 2024, disclosing its financial results for the first quarter of 2024. The press release is included as Exhibit 99.1.
Key Financial Metrics
The provided text is a cover sheet and does not contain specific financial data. The filing explicitly states that the detailed results are contained within the attached press release (Exhibit 99.1). Consequently, the following metrics are not available in this document:
- Revenue
- Profit/Loss
- Cash Flow
- Margins
- Debt and Liquidity
Note: The filing text does not provide a clear value for any specific financial metric.
Material Changes
No material changes or comparative data versus prior periods are detailed in this specific filing text. The document only references the issuance of the Q1 2024 results.
Guidance, Outlook, and Risks
Management Commentary: The filing notes the issuance of a press release regarding Q1 2024 results but does not summarize the content of that commentary.
Legal Status of Information: The information in this Item 2.02 and the attached press release is "furnished" and not "filed" under the Exchange Act. It is not subject to liability under Section 18 of the Exchange Act and is not incorporated by reference into other filings unless expressly stated.
Investor Verification Checklist
- Review Exhibit 99.1 (Press Release dated May 9, 2024) for actual Q1 2024 revenue, net loss, and cash position figures.
- Verify the Company's liquidity status and runway based on the cash balance reported in the press release.
- Check for any updates on clinical trial progress or regulatory milestones mentioned in the press release, as these are critical for a biopharmaceutical company.
- Confirm if the "furnished" status of the press release impacts the legal weight of any forward-looking statements contained therein.